Short answer. The Dangerous Drugs Board and the Department of Labor and Employment (DOLE) are jointly responsible for creating the guidelines that implement the National Drug-Free Workplace Program under RA 9165. The law also requires that funding for the program be included in the annual General Appropriations Act, so its implementation depends on yearly government budgeting.
What the law says
The Board and the DOLE shall formulate the necessary guidelines for the implementation of the national drug-free workplace program.
RA 9165, Section 48 — Workplace Program Guidelines. Read the full provision →
What the law says
The amount necessary for the implementation of which shall be included in the annual General Appropriations Act.
RA 9165, Section 48 — Workplace Program Guidelines. Read the full provision →
Who writes the guidelines
Section 48 assigns guideline-writing authority jointly to the Dangerous Drugs Board and the Department of Labor and Employment. Rather than leaving workplace drug policy to each employer to design independently, the law centralizes the framework at the national level, with DOLE contributing its labor and workplace expertise and the Board contributing its role as the lead agency on dangerous drugs policy under the Act.
How the program is funded
The section specifically ties implementation to the annual General Appropriations Act, meaning the national drug-free workplace program is not self-funding or funded through employer contributions alone. Its budget depends on what Congress allocates each fiscal year, which in practice can affect how quickly or how broadly DOLE and the Board are able to roll out workplace guidelines, training, and related support in a given year.
Where this fits for employers
This section is the source of the guidelines that employers are expected to follow when setting up a workplace drug prevention policy, a topic addressed separately in the provision on Drug-Free Workplace Policy. For a business owner or HR practitioner, Section 48 explains why workplace drug policies commonly trace back to a national framework rather than being purely a matter of internal company discretion, since the underlying guidelines originate from a joint Board-DOLE issuance covering testing procedures, referral for treatment, and employee education components.
What this provision does not cover
Section 48 does not itself list what a workplace policy must contain, does not create penalties for employers who lack one, and does not give employees an independent legal claim based solely on this provision. It is a guideline-issuing mandate directed at government agencies, not a self-executing rule that private employers can be sued under directly. Anyone assessing a specific workplace drug policy dispute needs to look at the implementing guidelines themselves, not just this section.
Why the joint agency structure matters
Placing this responsibility with two agencies rather than one is deliberate. The Dangerous Drugs Board supplies the substantive expertise on drugs and prevention, while DOLE supplies enforceability and familiarity with labor standards and workplace realities. That combination is meant to keep workplace drug guidelines both scientifically grounded and practically enforceable inside an employment relationship, rather than treating workplace drug policy as purely a criminal-law or purely a labor-law issue in isolation.
Related provisions
- RA 9165, Section 48 — Workplace Program Guidelines
- RA 9165, Section 47 — Drug-Free Workplace Policy
- RA 9165, Section 51 — Local Government Budget Support